News coverage about Natus Medical (NASDAQ:BABY) has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Natus Medical earned a news impact score of 0.11 on Accern’s scale. Accern also gave press coverage about the medical equipment provider an impact score of 46.1535586274166 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Natus Medical (BABY) opened at $39.85 on Monday. Natus Medical has a 1-year low of $31.65 and a 1-year high of $43.60. The company has a debt-to-equity ratio of 0.36, a current ratio of 4.21 and a quick ratio of 3.36. The firm has a market capitalization of $1,240.00, a PE ratio of 25.71 and a beta of 0.89.
Natus Medical (NASDAQ:BABY) last posted its earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.02. Natus Medical had a positive return on equity of 12.06% and a negative net margin of 0.62%. The company had revenue of $122.60 million for the quarter, compared to the consensus estimate of $122.41 million. During the same quarter in the prior year, the company earned $0.39 earnings per share. Natus Medical’s revenue was up 34.9% on a year-over-year basis. equities research analysts forecast that Natus Medical will post 1.74 EPS for the current year.
A number of research analysts have recently issued reports on the company. BidaskClub downgraded Natus Medical from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Zacks Investment Research raised Natus Medical from a “sell” rating to a “hold” rating in a report on Friday, September 22nd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. Natus Medical currently has an average rating of “Hold” and a consensus target price of $46.50.
In other Natus Medical news, VP Dong Chune Christopher Chung sold 12,642 shares of the company’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $42.91, for a total value of $542,468.22. Following the completion of the sale, the vice president now owns 141,414 shares in the company, valued at $6,068,074.74. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director William M. Moore sold 5,000 shares of the company’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $41.01, for a total value of $205,050.00. The disclosure for this sale can be found here. In the last three months, insiders sold 22,042 shares of company stock worth $902,266. 5.50% of the stock is owned by corporate insiders.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.